TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tobacco Treatment Using EMDR (ToTEM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Tobacco Use Disorder according to the DSM-5 (American Psychiatric Association, 2013) criteria.~* Age ≥ 18 years.~* Good Dutch language proficiency (based on clinical judgement).~* Smoking, on average, ≥ 10 cigarettes per day pre-admission.~* A score of at least 5 on a scale from 0 to 10, for motivation and self-efficacy~* A planned inpatient stay of ≥ 4 weeks.~* Written informed consent.~Exclusion Criteria:~• Serious therapy interfering behavior or symptoms that also interfere with TAU, based on clinical judgement (e. g. psychiatric or medical crisis that requires immediate intervention).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAU only: Community Reinforcement Approach (CRA) + a regular smoking cessation program (Type: ACTIVE_COMPARATOR): TAU only
- TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR) + TAU (CRA) (Type: EXPERIMENTAL): TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Consequences of Gastrointestinal Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have undergone previous oesophageal or gastric resection~Exclusion Criteria:~* Age \<18~* Recent history of untreated anaemia~* Donated blood in preceding 16 weeks~* Lack capacity to read and retain information about study~* Have a known allergy to interventional agent~* Have received a course of antibiotics in preceding two months~* Be on medication that interacts with intervention~* Have a history of C. difficile colitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Observational only (Type: NO_INTERVENTION): Oral glucose tolerance test, neurocognitive questionnaire tasks only.
- Somatostatin (Type: EXPERIMENTAL): Oral glucose tolerance test after 100mcg Somatostatin
- Antibiotics (Type: EXPERIMENTAL): Oral glucose tolerance test after treatment of small intestinal bacterial overgrowth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA status I, II or III~* Patients older than 18 years~* HIPEC for bowel surgery with oxaliplatin + dextrose 5% for a duration of 30 min~* Duration and type of surgery requiring an epidural analgesia via an epidural catheter placed and tunnelled prior the general anesthesia induction and an arterial line placed after induction of general anesthesia.~Exclusion Criteria:~* Any allergy to one drug used in our anesthesia or HIPEC protocol~* Any contra-indication or patient's refusal for epidural placement~* Chronic arrhythmic cardiac conditions~* Chronic pain with use of opioids more than 3 times per week for 4 weeks~* Bowel occlusion~* Physical/mental incapacities~* Unexpected difficult airway requesting excessive, possibly painful airway manipulations.~* Epidural failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monitored group M (optimized controlled anesthesia) (Type: ACTIVE_COMPARATOR): Patients in the Monitored group M, the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume.
- Control group C (standard of care anesthesia) (Type: ACTIVE_COMPARATOR): Patients in the Control group C will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-Hodgkin's or Hodgkin's lymphoma that has relapsed following either a course of high dose chemotherapy or autologous stem cell transplantation.~* \>= 90 days from prior transplant.~* Have a suitable human leukocyte antigen (HLA)-matched related bone marrow donor or a compatible matched unrelated bone marrow donor by molecular typing at HLA A, B, C, D, DR.~* Physically and psychologically capable of undergoing bone marrow transplantation and its attendant period of strict isolation.~* Age \>= 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Be able to receive 400 cGy Total Body Irradiation (TBI).~* Pulmonary function tests: Diffusing capacity or Transfer factor of the lung for carbon monoxide (DLCO) \>= 50% predicted, the forced expiratory volume in 1 second (FEV1) \>= 50% predicted.~* Left ventricular ejection fraction (LVEF) at least 45% by Multi Gated Acquisition Scan (MUGA) or echocardiogram.~* Renal function: creatinine clearance \> 50 ml/min.~* Liver function tests: \< 3 x Upper Limit of Normal (ULN). Liver function test include serum glutamic oxaloacetic transaminase (SGOT) (Aspartate transaminase (AST)), Serum Glutamic Pyruvate Transaminase (SGPT) (Alanine transaminase (ALT)), and bilirubin.~Exclusion Criteria:~* Human immunodeficiency virus positive (HIV+) patients (test positive for P21 antibodies to HIV).~* Evidence of active infection (have received parenteral antibiotics \<= 2 weeks prior to registration).~* Pregnant or breast-feeding women.~* Curable with any other therapeutic interventions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transplant (Type: EXPERIMENTAL): Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MemoryXL Effects on Mild Cognitive Impairment Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MCI patients diagnosed at the VAMC Center for Alzheimers and Neurodegenerative Disorder (CANDO).~* Clinical Dementia Rating (CDR) score of 0.5.~* fluent in English.~* able to ambulate to the outpatient clinic and research laboratory~* have sight and hearing levels sufficient to complete neuropsychological testing.~* free from bipolar disorder and terminal illnesses such as cancer.~* must live with a spouse or adult relative who will record nutriceutical ingestion daily.~* subjects will be consecutively diagnosed patients from all ethnic groups.~Exclusion Criteria:~* patients from protected categories such as prisoners and pregnant women.~* any MCI subject who develops a life-threatening disease such as terminal cancer, stroke, brain trauma, debilitating heart attack, etc.~* indication of inability to make decisions regarding study participation.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Memory XL (Type: EXPERIMENTAL): Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion.
- placebo (Type: PLACEBO_COMPARATOR): Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptoms consistent with stroke with known onset \< 12 hours prior to enrollment and planned recording with the Nautilus NeuroWave System~* Suspected pathology of following vessels: internal carotid artery, ACA, MCA, PCA, basilar or other anterior or posterior cerebral vessels or normal anatomy~* Subject is planned to undergo standard stroke triage imaging protocol~* Able to understand and provide signed informed consent, or have a Legally Authorized Representative willing to provide informed consent on subject's behalf~Exclusion Criteria:~* Known to meet hospital criteria for brain death~* Not a candidate for CT, MRI~* unknown time of stroke symptom onset.~* Psychologically unstable and not able to cooperate~* Not suitable for participation in this study in the opinion of the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with Stroke Symptoms (Type: None): Suspected stroke subjects that present to hospital with stroke symptoms and are evaluated for stroke
- Normal Cohort (Type: None): Subjects that are not being evaluated for stroke and are confirmed to have no cerebrovascular disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the hip, knee, or spine for 1 year or longer, confirmed by radiographic evidence within the last 2 years.~* Good pain control while on a stable dose of an opioid analgesic for osteoarthritis.~Exclusion Criteria:~* Not currently taking and tolerating opioids.~* Taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days of enrollment.~* Requiring frequent analgesic therapy for chronic condition(s), in addition to osteoarthritis.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BTDS 5 (Type: ACTIVE_COMPARATOR): Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
- BTDS 20 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
- Oxycodone Immediate-Release (Oxy IR) 40 mg (Type: EXPERIMENTAL): Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Velcade in Myelodysplastic Syndrome - Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 -75 years.~* Patients with the following clinical diagnosis: RA(FAB) or RCMD (WHO), RARS (FAB) or RCDM-RS(WHO), RAEB (FAB) or RAEB I (WHO), RAEB II (WHO), and:~  * IPSS intermediate-2 (score 1.5-2) or high (score 2.5-3) not previously treated with chemotherapy (CT) and not eligible for intensive chemotherapy or allogeneic stem cell transplantation (SCT), or~ * IPSS intermediate-1(score 0.5-1) or low (score 0), EPO or immunosuppressive (Cyclosporine, CSA; anti-tymocyte globulin, ATG) therapies resistant or not eligible for these therapies, and transfusion dependent.~* Patients willing and able to comply with the protocol requirements.~* Patients given voluntary written informed consent to participate in the study, with the understanding that consent may be withdrawn at any time without prejudice to future medical care.~* Male and female patients willing to use acceptable methods for contraception, for the duration of the study.~* Patients with WHO performance Status (PS) 0-2, and life expectancy \> 3 months.~* Renal function tests ≤ 2 x upper limit of normal values.~* AST/GOT, ALT/GPT ≤ 2.5 x upper limit of normal values.~* Total bilirubine ≤ 1.5 x upper limit of normal value.~Exclusion Criteria:~* Patient has Grade 2 (as defined by the NCI Common Toxicity Criteria-CTC) peripheral neuropathy within 14 days before enrollment.~* Patient has hypersensitivity to bortezomib, boron or mannitol.~* Patient has received prior treatment with bortezomib~* Patient is pregnant or nursing~* Patient has received other investigational drugs within 14 days before enrollment~* Patient has received prior chemotherapy~* Patient had a major surgery within 4 weeks before enrollment~* Patient had myocardial infarction within 6 months of enrollment or has class III-IV heart failure, uncontrolled angina or arrhythmias~* Patient has been treated for previous malignancy within 5 years before enrollment~* Patient has uncontrolled hypertension or diabetes mellitus~* Patient is known to have HBV or HCV active hepatitis or is human immunodeficiency virus (HIV)-positive~* Patient has systemic infections requiring treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Primary Fibromyalgia (2010 ACR criteria)~* Male or female 18-75 years old~* Patients currently receiving pharmacologic treatment for depression should have been clinically stable for at least 3 months prior to randomization, and on stable doses of antidepressants during this 3 month time frame.~* Willing and able to withdraw specific therapies (ask PI)~* If female, medically acceptable form of contraception or not of child bearing potential.~* Provide written informed consent to participate.~* Willing and able to comply with all protocol specified requirement.~Exclusion Criteria:~* Arthritis, lupus and other systemic auto-immune diseases~* Regional or persistent pain that could interfere with assessment of fibromyalgia pain~* Bipolar and psychotic disorders~* Increased risk of suicide~* Significant clinical (cardiac, systemic infection, systemic corticosteroid requirement, drug/alcohol abuse) or laboratory abnormalities.~* Inability to wash-out specific medications (ask PI)~* Known hypersensitivity to cyclobenzaprine~* Others: seizure disorders, severe/untreated sleep apnea, BMI\>45

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TNX-102 SL Tablet, 2.8 mg (Type: EXPERIMENTAL): 1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
- Placebo SL Tablet (Type: PLACEBO_COMPARATOR): 1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: PPAR-gamma: a Novel Therapeutic Target for Asthma?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75 of either sex with a clinical diagnosis of asthma,~* FEV1 ≥ 60% predicted and an increase in FEV1 of greater than 12% following inhaled salbutamol 400μg or Peak Expiratory Flow (PEF) variability \>12% during run-in.~* Allowed medication: 0-800μg inhaled beclomethasone diproprionate or equivalent and as required short acting beta agonist.~Exclusion Criteria:~* Current smoking,~* \> 10 pack years smoking history,~* Treatment with leukotriene antagonists,~* Liver or cardiovascular disease,~* Oral steroid treatment or exacerbation within 6 weeks,~* Females who are pregnant, lactating or not using adequate contraception,~* Any contra-indication to pioglitazone (hypersensitivity to pioglitazone, cardiac failure, history of cardiac failure, hepatic impairment, diabetic ketoacidosis),~* Oral or insulin treatment for diabetes,~* Treatment with gemfibrozil or rifampicin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IMP Pioglitazone (Type: EXPERIMENTAL): Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Steam Inhalations in COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with a SARS-CoV-2 positive molecular swab carried out in the previous 48 hours before the enrollement~* Adults with mild infection~* Adults with symptoms such as fever above 37 ° C, feeling bad, cold symptoms (cough, pharyngodynia, nasal congestion), headache, myalgia, diarrhea, anosmia, dysgeusia~* Adults without the above symptoms~Exclusion Criteria:~* Adults with dyspnea and/or dehydration and/or alterations in consciousness and/or sepsis.~* Subjects with severe asthma~* Subjects and with contraindications to treatment with steam inhalations~* Multi-allergic subjects~* Subjects unable to complete the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): Steam inhalations
- Control arm (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Deprivation and Advancement of Sleep Period as Treatment for Bipolar Depression.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bipolar disorder, depressive phase~Exclusion Criteria:~* substance abuse, psychotic symptoms, suicidal intentions, active mania/hypomania.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sleep deprivation (Type: EXPERIMENTAL): Sleep deprivation and sleep phase advancement
- usual treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues